Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept 2025 revenue rises to $761.4 million, net income falls to $99.7 million

Mixed Impact 3 of 5 earnings Written later

Corcept reported fourth quarter and full-year 2025 results with revenue up from 2024 but net income and diluted earnings per share down. The company also gave 2026 revenue guidance of $900 million to $1,000 million, and said its Cushing's syndrome business was constrained by specialty pharmacy capacity and a fourth-quarter pharmacy transition.

Key points

  • Full-year 2025 revenue was $761.4 million, up from $675.0 million in 2024.
  • Full-year 2025 net income was $99.7 million, or $0.82 diluted per share, down from $141.2 million, or $1.23 diluted per share, in 2024.
  • Fourth-quarter 2025 revenue was $202.1 million, up from $181.9 million; fourth-quarter net income was $24.3 million, or $0.20 diluted per share, down from $30.7 million, or $0.26.
  • Full-year 2026 revenue guidance is $900 million to $1,000 million; cash and investments were $532.4 million at December 31, 2025.

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECFeb 24, 2026, 4:10 PM ET
Accession number0001628280-26-011080

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 24, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.